New Horizons in International Business series
Edited by Daniel R. Cahoy and Lynda J. Oswald
Chapter 9: Biopharmaceuticals under the Patient Protection and Affordable Care Act: determining the appropriate market and data exclusivity periods
With the enactment of the Biologics Price Competition and Innovation Act of 2009 (BPCIA) in March 2010 as part of the Patient Protection and Affordable Care Act (Patient Protection and Affordable Care Act, 2010), manufacturers of follow-on protein products, meaning biopharmaceuticals that are similar to branded biologic products, will be able to file abbreviated applications for US Food and Drug Administration (FDA) approval for their products. This abbreviated approval process will allow manufacturers of follow-on protein products, also known as biosimilars, to avoid at least some, though not necessarily all, of the costly pre-clinical and clinical testing necessary for regulatory approval by relying on data generated by branded products. Even after enactment of the BPCIA, however, confusion remains regarding two of its most debated provisions, those relating to the periods of market and data exclusivity to which innovator pharmaceutical firms are entitled under the statute. Data exclusivity is defined as the period of time that an innovator pharmaceutical firm’s pre-clinical and clinical data cannot be relied upon by a follow-on competitor in its application for FDA approval.
You are not authenticated to view the full text of this chapter or article.
Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.
Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.
Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.